Abbott Laboratories (GB:0Q15)
LSE:0Q15
Holding GB:0Q15?
Track your performance easily

Abbott Laboratories (0Q15) Share Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

0Q15 Analyst Ratings

Strong Buy
17Ratings
14 Buy
3 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Abbott
Laboratories
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0Q15 Stock 12 Month Forecast

Average Price Target

$129.06
▲(11.00% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Abbott Laboratories in the last 3 months. The average price target is $129.06 with a high forecast of $143.00 and a low forecast of $107.00. The average price target represents a 11.00% change from the last price of $116.27.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"88":"$88","102":"$102","116":"$116","130":"$130","144":"$144"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$129.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":107,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$107.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[88,102,116,130,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2024","6":"Apr<br/>2024","9":"Jul<br/>2024","12":"Oct<br/>2024","25":"Oct<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.29,114.6523076923077,117.0146153846154,119.37692307692308,121.73923076923077,124.10153846153847,126.46384615384616,128.82615384615386,131.18846153846155,133.55076923076922,135.91307692307691,138.2753846153846,140.6376923076923,{"y":143,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.29,113.58000000000001,114.87,116.16000000000001,117.45,118.74000000000001,120.03,121.32000000000001,122.61,123.9,125.19,126.48,127.77,{"y":129.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,112.29,111.88307692307693,111.47615384615385,111.06923076923077,110.66230769230769,110.25538461538461,109.84846153846154,109.44153846153847,109.03461538461539,108.62769230769231,108.22076923076924,107.81384615384616,107.40692307692308,{"y":107,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":89.393,"date":1697155200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.535,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.066,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":108.88,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.485,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.142,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109.476,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.347,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.566,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.716,"date":1720137600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":110.11,"date":1722556800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.369,"date":1725580800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.29,"date":1728000000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$143.00Average Price Target$129.06Lowest Price Target$107.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley
$107
Hold
-7.97%
Downside
Assigned
09/10/24
Hold Rating on Abbott Laboratories Amid Lingo's Launch: Balancing Positive User Experience with Market Challenges
BTIG
$135
Buy
16.11%
Upside
Reiterated
08/22/24
BTIG reiterates Buy Rating on Abbott Labs (ABT)BTIG analyst Marie Thibault reiterated a Buy rating and $135.00 price target on Abbott Labs (NYSE: ABT).
Barclays
$140$143
Buy
22.99%
Upside
Assigned
07/31/24
Barclays Sticks to Their Buy Rating for Abbott Laboratories (ABT)
Edward Jones
Hold
Downgraded
07/29/24
Abbott downgraded to Hold from Buy at Edward JonesAbbott downgraded to Hold from Buy at Edward Jones
Bank of America Securities
$133
Buy
14.39%
Upside
Assigned
07/29/24
Analysts Offer Insights on Healthcare Companies: 2seventy bio (NASDAQ: TSVT) and Abbott Laboratories (NYSE: ABT)

Best Analysts Covering Abbott Laboratories

Which Analyst Should I Follow If I Want to Buy GB:0Q15 and Sell After:
1 Month
xxx
Success Rate
16/22 ratings generated profit
73%
Average Return
+1.15%
assigned a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +1.15% per trade.
3 Months
xxx
Success Rate
19/22 ratings generated profit
86%
Average Return
+5.88%
assigned a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 86.36% of your transactions generating a profit, with an average return of +5.88% per trade.
1 Year
Jayson BedfordRaymond James
Success Rate
41/47 ratings generated profit
87%
Average Return
+19.47%
reiterated a buy rating 6 months ago
Copying Jayson Bedford's trades and holding each position for 1 Year would result in 87.23% of your transactions generating a profit, with an average return of +19.47% per trade.
2 Years
xxx
Success Rate
28/34 ratings generated profit
82%
Average Return
+17.41%
assigned a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 82.35% of your transactions generating a profit, with an average return of +17.41% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0Q15 Analyst Recommendation Trends

Rating
Jun 24
Jul 24
Aug 24
Sep 24
Oct 24
Strong Buy
0
0
0
0
0
Buy
31
30
27
24
18
Hold
1
3
4
6
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
33
31
30
21
In the current month, 0Q15 has received 18 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0Q15 average Analyst price target in the past 3 months is $129.06.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0Q15 Financial Forecast

0Q15 Earnings Forecast

Next quarter’s earnings estimate for 0Q15 is $1.20 with a range of $1.18 to $1.23. The previous quarter’s EPS was $1.14. 0Q15 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.00% of the time in the same period. In the last calendar year 0Q15 has Outperformed its overall industry.
Next quarter’s earnings estimate for 0Q15 is $1.20 with a range of $1.18 to $1.23. The previous quarter’s EPS was $1.14. 0Q15 beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 42.00% of the time in the same period. In the last calendar year 0Q15 has Outperformed its overall industry.

0Q15 Sales Forecast

Next quarter’s sales forecast for 0Q15 is $10.55B with a range of $10.48B to $10.79B. The previous quarter’s sales results were $10.38B. 0Q15 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 45.21% of the time in the same period. In the last calendar year 0Q15 has Outperformed its overall industry.
Next quarter’s sales forecast for 0Q15 is $10.55B with a range of $10.48B to $10.79B. The previous quarter’s sales results were $10.38B. 0Q15 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 45.21% of the time in the same period. In the last calendar year 0Q15 has Outperformed its overall industry.

0Q15 Stock Forecast FAQ

What is GB:0Q15’s average 12-month price target, according to analysts?
Based on analyst ratings, Abbott Laboratories’s 12-month average price target is $129.06.
    What is GB:0Q15’s upside potential, based on the analysts’ average price target?
    Abbott Laboratories has 11.00% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Abbott Laboratories a Buy, Sell or Hold?
          Abbott Laboratories has a consensus rating of Strong Buy, which is based on 14 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Abbott Laboratories’s share price target?
            The average share price target for Abbott Laboratories is $129.06. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $143.00 ,and the lowest forecast is $107.00. The average share price target represents 11.00% Increase from the current price of $116.27.
              What do analysts say about Abbott Laboratories?
              Abbott Laboratories’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of Abbott Laboratories?
                To buy shares of GB:0Q15, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis